Why the study?
With increasing use of extracorporeal renal replacement therapies, clinicians face uncertainty regarding whether biomarker removal impacts their reliability in guiding sepsis diagnosis and treatment.
Are sepsis biomarkers reliable for guiding diagnosis and treatment in critically ill patients receiving extracorporeal therapies?
Population
Critically ill patients receiving extracorporeal therapies (renal replacement therapy)
Design
Review
Authors
Loading...
RRT may alter biomarker levels in ICU patients; leaves open their diagnostic reliability pending targeted validation.
Are sepsis biomarkers reliable for guiding diagnosis and treatment in critically ill patients receiving extracorporeal therapies?
Clinicians must consider the molecular weight cut-offs of different renal replacement therapies when interpreting sepsis biomarkers in critically ill patients.
Honoré et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: